Methods for diagnosing and treating prostate cancer
US-2015313878-A1 · Nov 5, 2015 · US
Targeting cell tropism receptors to inhibit cytomegalovirus infection
US11484570B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-11484570-B2 |
| Application number | US-201816604735-A |
| Country | US |
| Kind code | B2 |
| Filing date | Apr 13, 2018 |
| Priority date | Apr 14, 2017 |
| Publication date | Nov 1, 2022 |
| Grant date | Nov 1, 2022 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
Methods for treating or reducing the risk of a cytomegalovirus infection in a subject that include administering one or more of an inhibitor of Deleted in Malignant Brain Tumors 1 (DMBT1), an inhibitor of OR14I1, or an inhibitor of adenylyl cyclases.
First claim
Opening claim text (preview).
What is claimed is: 1. A method of treating or reducing the risk of a cytomegalovirus (CMV) infection in a mammalian subject, the method comprising administering to the subject a therapeutically effective amount of one or more of an inhibitor of Olfactory Receptor Family 14 Subfamily I Member 1 (OR14I1), wherein the inhibitor of OR14I1 is an N-terminal peptide of OR14I1 comprising the amino acid sequence MDNLTKVTEFLLMEFSGIWELQVLHA (SEQ ID NO:1), or an active fragment thereof. 2. The method of claim 1 , wherein the active fragment comprises FLLMEFSGIWELQ (SEQ ID NO:3), LLMEFSGIWELQV (SEQ ID NO:4), LMEFSGIWELQVL (SEQ ID NO:5), or LMEFSGIWELQ (SEQ ID NO:6).
Assignees
Inventors
Classifications
against receptors, cell surface antigens or cell surface determinants · CPC title
comprising antibodies · CPC title
Antagonist effect on antigen, e.g. neutralization or inhibition of binding · CPC title
interfering nucleic acids [NA] · CPC title
- A61K38/177Primary
Receptors; Cell surface antigens; Cell surface determinants · CPC title
Patent family
Related publications grouped by family.
External sources
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US11484570B2 cover?
- Methods for treating or reducing the risk of a cytomegalovirus infection in a subject that include administering one or more of an inhibitor of Deleted in Malignant Brain Tumors 1 (DMBT1), an inhibitor of OR14I1, or an inhibitor of adenylyl cyclases.
- Who is the assignee on this patent?
- Univ Massachusetts
- What technology area does this patent fall under?
- Primary CPC classification A61K38/177. Mapped technology areas include Human Necessities.
- When was this patent published?
- Publication date Tue Nov 01 2022 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 1 related publication on this page (citations in our corpus or others sharing the same primary CPC).